Up to 60000 participants! Johnson & Johnson will launch the largest clinical trial of the new crown vaccine in September

Johnson & Johnson（ JNJ.US ) it is planned novel coronavirus pneumonia vaccine candidate will be the three largest clinical phase in early September. The J & J trial will be the largest trial of the new crown vaccine so far. Pharmaceutical company Moderna（ MRNA.US ）Pfizer（ PFE.US ）The two companies said they had recruited about 30000 people in a phase III clinical trial of the candidate vaccine last month. < / P > < p > according to the company, preclinical trials have shown that its candidate vaccine can produce a higher level of antibody response with only one dose compared with other new crown vaccine studies. < / P > < p > the company expects to produce 600 million to 900 million doses of vaccine by April 2021 if the vaccine research and development work goes smoothly. It aims to provide more than one billion doses of vaccine worldwide by 2021, provided it is safe and effective. At the beginning of this month, Johnson & Johnson announced that it had reached an agreement with the U.S. government on the production and delivery of 100 million doses of vaccine worth more than 1 billion US dollars. At the same time, the U.S. government could choose to purchase an additional 200 million doses, but Johnson & Johnson did not disclose the amount of this part of the purchase agreement. At the same time, the European Commission announced recently that it had completed preliminary negotiations on the purchase of 200 million doses of vaccine under development from Johnson & Johnson. Once the vaccine is proven to be safe and effective, the European Commission may place a formal order on behalf of the 27 member states.

is aware that the EU is calling about 2 billion euros from an emergency fund to try to finalize a pre order agreement with a number of vaccine manufacturers to win sufficient vaccine supply for the EU’s 450 million population. In addition, the Brazilian health regulator Anvisa said on August 18 that it had approved a candidate vaccine developed by Johnson Johnson’s subsidiary Janssen for human clinical trials.